Effect of Rosuvastatin Therapy on Troponin I Release Following Percutaneous Coronary Intervention in Nonemergency Patients (from the TIP 3 Study)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F14%3A10227340" target="_blank" >RIV/00064203:_____/14:10227340 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/14:10227340 RIV/00216208:11140/14:10227340 RIV/00669806:_____/14:10227340 RIV/00216224:14110/14:00081970

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.amjcard.2013.10.026" target="_blank" >http://dx.doi.org/10.1016/j.amjcard.2013.10.026</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.amjcard.2013.10.026" target="_blank" >10.1016/j.amjcard.2013.10.026</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of Rosuvastatin Therapy on Troponin I Release Following Percutaneous Coronary Intervention in Nonemergency Patients (from the TIP 3 Study)

Popis výsledku v původním jazyce

Several randomized studies have suggested that pretreatment with statins may reduce a periprocedural biomarker release in patients who underwent percutaneous coronary intervention (PCI); however, results remain controversial. The purpose of this study was to investigate the effect of a 1-day rosuvastatin therapy on troponin I release in patients who underwent nonemergency PCI. A total of 445 patients with angina pectoris were randomly assigned to therapy with rosuvastatin (20 mg 12 hours before coronaryangiography + 20 mg immediately before PCI; rosuvastatin group, 220 patients) or PCI without statin therapy (control group, 225 patients). In patients taking statins (73%), rosuvastatin was added to their long-term statin therapy. The primary end pointwas the incidence of TnI microleak defined as TnI elevation >1.5 x upper limit of normal, and the secondary end point was the incidence of post-PCI TnI elevation >3 x upper limit of normal. The incidence of primary and secondary end point

Název v anglickém jazyce

Effect of Rosuvastatin Therapy on Troponin I Release Following Percutaneous Coronary Intervention in Nonemergency Patients (from the TIP 3 Study)

Popis výsledku anglicky

Several randomized studies have suggested that pretreatment with statins may reduce a periprocedural biomarker release in patients who underwent percutaneous coronary intervention (PCI); however, results remain controversial. The purpose of this study was to investigate the effect of a 1-day rosuvastatin therapy on troponin I release in patients who underwent nonemergency PCI. A total of 445 patients with angina pectoris were randomly assigned to therapy with rosuvastatin (20 mg 12 hours before coronaryangiography + 20 mg immediately before PCI; rosuvastatin group, 220 patients) or PCI without statin therapy (control group, 225 patients). In patients taking statins (73%), rosuvastatin was added to their long-term statin therapy. The primary end pointwas the incidence of TnI microleak defined as TnI elevation >1.5 x upper limit of normal, and the secondary end point was the incidence of post-PCI TnI elevation >3 x upper limit of normal. The incidence of primary and secondary end point

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

American Journal of Cardiology

ISSN

0002-9149

e-ISSN

—

Svazek periodika

113

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

446-451

Kód UT WoS článku

000331161700007

EID výsledku v databázi Scopus

—